Aclaris Therapeutics, Inc. (ACRS) Operating Margin
- Operating margin · 12 months: Value -1050.16%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -1050.16% | Operating income / revenue. Period ending 2026-06-30. $-86.31M ÷ $8.22M × 100 ≈ -1050.16% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -86.31M USD | Operating Income (Loss) |
| Revenue | 8.22M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 63.34M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-86.31M | $8.22M | (m) | $63.34M | (m) | -1050.16% |
| 2026-03-31 | $-80.48M | $8.37M | (m) | $56.72M | (m) | -961.91% |
| 2025-12-31 | $-76.38M | $7.83M | (m) | $52.65M | (m) | -975.91% |
| 2025-09-30 | $-153.32M | $15.74M | (m) | $45.09M | (m) | -973.93% |
| 2025-06-30 | $-146.64M | $16.79M | (m) | $38.02M | (m) | -873.42% |
| 2025-03-31 | $-141.09M | $17.78M | (m) | $35.33M | (m) | -793.64% |
| 2024-12-31 | $-141.93M | $18.72M | (m) | $33.59M | (m) | -758.18% |
| 2024-09-30 | $-46.30M | $27.08M | (m) | $51.21M | (m) | -171.00% |
| 2024-06-30 | $-67.41M | $32.02M | (m) | $69.13M | (m) | -210.56% |
| 2024-03-31 | $-86.37M | $31.12M | (m) | $85.64M | (m) | -277.55% |
| 2023-12-31 | $-97.36M | $31.25M | (m) | $98.38M | (m) | -311.55% |
| 2023-09-30 | $-122.39M | $21.43M | (m) | $92.81M | (m) | -571.06% |
| 2023-06-30 | $-111.69M | $31.17M | (m) | $92.59M | (m) | -358.34% |
| 2023-03-31 | $-100.86M | $30.83M | (m) | $86.09M | (m) | -327.20% |
| 2022-12-31 | $-89.85M | $29.75M | (m) | $77.81M | (m) | -302.01% |
| 2022-09-30 | $-83.67M | $23.50M | (m) | $70.84M | (m) | -356.03% |
| 2022-06-30 | $-83.09M | $6.14M | (m) | $61.16M | (m) | -1353.02% |
| 2022-03-31 | $-80.10M | $6.44M | (m) | $50.28M | (m) | -1244.38% |
| 2021-12-31 | $-89.72M | $6.76M | (m) | $43.81M | (m) | -1327.07% |
| 2021-09-30 | $-80.39M | $6.84M | (m) | $41.06M | (m) | -1175.29% |
| 2021-06-30 | $-70.56M | $6.63M | (m) | $33.32M | (m) | -1064.25% |
| 2021-03-31 | $-63.94M | $6.85M | (m) | $31.89M | (m) | -933.09% |
| 2020-12-31 | $-50.91M | $6.48M | (m) | $31.73M | (m) | -785.44% |
| 2020-09-30 | $-54.91M | $6.00M | (m) | $34.34M | (m) | -915.54% |
| 2020-06-30 | $-67.30M | $5.53M | (m) | $43.65M | (m) | -1216.81% |
| 2020-03-31 | $-99.51M | $4.37M | (m) | $54.70M | (m) | -2276.66% |
| 2019-12-31 | $-111.06M | $4.23M | (m) | $64.90M | (m) | -2627.35% |
| 2019-09-30 | $-168.18M | $8.84M | (m) | $74.86M | (m) | -1901.66% |
| 2019-06-30 | $-159.61M | $16.20M | (m) | $72.96M | (m) | -985.09% |
| 2019-03-31 | $-141.80M | $14.01M | (m) | $69.32M | (m) | -1011.85% |
| 2018-12-31 | $-135.41M | $10.09M | (m) | $63.01M | (m) | -1341.93% |
| 2018-09-30 | $-121.82M | $7.42M | (m) | $56.66M | (m) | -1641.53% |
| 2018-06-30 | $-107.12M | $6.48M | (m) | $51.64M | (m) | -1653.91% |
| 2018-03-31 | $-90.44M | (m) | (m) | $45.62M | (m) | (m) |
| 2017-12-31 | $-72.42M | $1.68M | (m) | $39.79M | (m) | -4303.21% |
| 2017-09-30 | $-58.61M | (m) | (m) | $33.54M | (m) | (m) |
| 2017-06-30 | $-50.66M | (m) | (m) | $29.84M | (m) | (m) |
| 2017-03-31 | $-48.36M | (m) | (m) | $31.71M | (m) | (m) |
| 2016-12-31 | $-48.57M | (m) | (m) | $33.48M | (m) | (m) |
| 2016-09-30 | $-41.74M | (m) | (m) | $28.93M | (m) | (m) |
| 2016-06-30 | $-41.57M | (m) | (m) | $31.18M | (m) | (m) |
| 2016-03-31 | $-31.18M | (m) | (m) | $23.14M | (m) | (m) |
| 2015-12-31 | $-20.67M | (m) | (m) | $15.34M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-8.53M | (m) | (m) | $6.51M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-5.26M | (m) | (m) | $3.49M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |